CÁNCER DE MAMA LUMINAL
TIPO
ENSAYO
FASE
ESTADO
ADYUVANCIA
CAMBRIA-2: An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer
Fase 3
ABIERTO
ELEGANT: A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Fase 3
ABIERTO
METASTÁSICO
MIRADOR: A PoC Study to Evaluate Treatments’ Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population
Fase 2
ABIERTO
RLY-2608: Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Fase 3
ABIERTO
MEN2312-01: A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
Fase 1
ABIERTO
CADILLAC: Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cance
Fase 2
ABIERTO
INAVO 123: A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Fase 3
ABIERTO
PIKTURE 1: First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
Fase 1
ABIERTO
ELAINE 3: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Fase 3
ABIERTO
ADELA: Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i
Fase 3
ABIERTO
BREAKER101: Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Fase 1
ABIERTO
PONTIAC: Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
Fase 2
ABIERTO
GO46021: A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Fase 1 B-2
ABIERTO
OPERA-02: Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Fase 3
ABIERTO
BNT326-01:Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
Fase 1
ABIERTO
CÁNCER DE MAMA TRIPLE NEGATIVO
TIPO
ENSAYO
FASE
ESTADO
NEOADYUVANCIA
MK2870-032: A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Fase 3
ABIERTO
ADYUVANCIA
ASCENT-05: Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
Fase 3
ABIERTO
BNT327-05 (ROSSETA):ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Fase 3
ABIERTO
MK2870-012:Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Fase 3
ABIERTO
METASTÁSICO
TROPION-Breast 05: A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator’s Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
Fase 3
ABIERTO
MK2870-011: A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Fase 3
ABIERTO
BL-B01D1 LUNG-101: A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
Fase 1
ABIERTO
IZABRIGHT-BREAST01: A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Fase 3
ABIERTO
BNT326-01: Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
Fase 1
ABIERTO
DIAMOND: Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer
Fase 2
ABIERTO
CÁNCER DE HER 2 POSITIVO
TIPO
ENSAYO
FASE
ESTADO
METASTÁSICO
C5731006:A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
Fase 1 B-2
ABIERTO
WO46069:RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
Fase 2-3
ABIERTO
EMPOWHER-303:A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician’s Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
Fase 3
ABIERTO
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Fase 2
ABIERTO
BREAKER101: Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Fase 1
ABIERTO
CÁNCER DE PULMÓN
TIPO
ENSAYO
FASE
ESTADO
METASTÁSICO
REPOSE: REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain metastasis (REPOSE)
Fase 2
ABIERTO
BL-B01D1 LUNG-101: A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
Fase 1
ABIERTO
MELANOMA
TIPO
ENSAYO
FASE
ESTADO
METASTÁSICO
LEON:Randomised, Multicentre, Multinational, Double-Blind Integrated Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 (Proposed Nivolumab Biosimilar) Versus EU-/US-Opdivo in Subjects With Previously Untreated Advanced (Unresectable or Metastatic) Melanoma (LEON Study) |
CJPB898A12101:Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®
Fase 3
ABIERTO
HEMATOLOGÍA
TIPO
ENSAYO
FASE
ESTADO
EXS73565: Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Fase 1
ABIERTO